<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538096</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP137</org_study_id>
    <nct_id>NCT00538096</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma</brief_title>
  <official_title>A Phase I, Multicenter, Open-Label, Single-Arm, Dose-Escalation, Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 in Adults With B-Cell Non-Hodgkin's Lymphoma Not Eligible for Curative Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Evaluate the safety and tolerability of multiple doses of MEDI-538 by continuous IV&#xD;
           infusion for 4 or 8 weeks in adult patients with B-cell NHL not eligible for curative&#xD;
           therapy.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of MEDI-538 administered by continuous IV infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Evaluate the safety and tolerability of MEDI-538 at doses of 5, 10, or 15 μg/m2/24h by&#xD;
           continuous IV infusion for 4 or 8 weeks in adult patients with B-cell NHL not eligible&#xD;
           for&#xD;
&#xD;
        -  Determine the MTD of MEDI-538 administered by continuous IV infusion for 4 or 8 weeks in&#xD;
           adult patients with B-cell NHL not eligible for curative therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Replacing this trial with a new trial.&#xD;
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All endpoints will be analyzed descriptively. AEs and SAEs will be summarized by dose cohort, body system, severity, and relationship to MEDI-538 through 30 days after discontinuation of MEDI-538.</measure>
    <time_frame>30 days after discontinuation of MEDI-538</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints of this study include measurement of the pharmacokinetics,immunogenicity, and antitumor activity of MEDI-538 in this patient population.</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-538</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-538</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-538</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-538</intervention_name>
    <description>1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-538</intervention_name>
    <description>1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-538</intervention_name>
    <description>1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men or women at least 18 years of age;&#xD;
&#xD;
          -  Written informed consent and Heath Insurance Portability and Accountability Act&#xD;
             (HIPAA) authorization (applies to covered entities in the US only) obtained from the&#xD;
             patient prior to performing any study-related procedures, including screening visits;&#xD;
&#xD;
          -  Histologically confirmed B-cell NHL of one of the following classifications:&#xD;
&#xD;
               -  Follicular lymphoma&#xD;
&#xD;
               -  Marginal zone lymphoma;&#xD;
&#xD;
               -  Lymphoplasmocytic lymphoma; or&#xD;
&#xD;
               -  Mantle cell lymphoma.&#xD;
&#xD;
          -  Not eligible for curative therapy according to the NCCN guidelines for NHL (NCCN&#xD;
             2006);&#xD;
&#xD;
          -  Measurable disease (at least one lesion ≥ 20 mm in one dimension) documented by&#xD;
             computed tomography (CT) scan;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (see Appendix A);&#xD;
&#xD;
          -  Life expectancy of at least 6 months;&#xD;
&#xD;
          -  Heterosexual sexually active females, unless surgically sterile or at least 1 year&#xD;
             postmenopausal, must use an effective method of avoiding pregnancy (including oral or&#xD;
             implanted contraceptives, intrauterine device, female condom, diaphragm with&#xD;
             spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile&#xD;
             sexual partner) for 21 days prior to the first dose of study drug, and must agree to&#xD;
             continue using such precautions through 3 months after the last dose of MEDI-538.&#xD;
             Cessation of birth control after this point should be discussed with a responsible&#xD;
             physician. Heterosexual sexually active males, unless surgically sterile, must&#xD;
             likewise use an effective method of birth control (condom) and must agree to continue&#xD;
             using such precautions through 3 months after the last dose of MEDI-538;&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL; absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L; platelets ≥&#xD;
             100.0 × 10^9/L; lymphocyte count ≥ 0.8 × 10^9/L; leukocyte count ≥ 3.0 × 10^9/L; and&#xD;
             D-dimer ≤ 2.5 × upper limit of normal (ULN); and antithrombin III ≥ lower limit of&#xD;
             normal (LLN); and 10. Total bilirubin ≤ 1.5 × ULN; aspartate transaminase (AST),&#xD;
             alanine transaminase (ALT), amylase and lipase ≤ 2 × ULN; serum creatinine ≤ 2 × ULN,&#xD;
             and creatinine clearance ≥ 50 mL/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of MEDI-538 in any previous clinical study;&#xD;
&#xD;
          -  History of allergy or reaction to any component of the MEDI-538 formulation;&#xD;
&#xD;
          -  Any other NHL not listed in inclusion criterion 3;&#xD;
&#xD;
          -  History of malignancy other than B-cell NHL within 5 years prior to study entry, with&#xD;
             the exception of basal cell carcinoma of the skin or carcinoma in situ of the cervix&#xD;
             successfully treated with curative therapy;&#xD;
&#xD;
          -  Known or suspected CNS involvement by NHL;&#xD;
&#xD;
          -  Clinical history of significant CNS pathology, eg, multiple occurrences of confusion,&#xD;
             dementia, multiple previous infarcts, or major brain surgery;&#xD;
&#xD;
          -  Active infection or known bacteremia. Patients with documented evidence of culture&#xD;
             positive sepsis or active infection requiring IV antibiotic therapy must complete a&#xD;
             full course of antibiotic treatment with no clinical or laboratory evidence of&#xD;
             bacterial infection at least 2 weeks prior to starting therapy with MEDI-538.&#xD;
&#xD;
          -  Vaccination (either preventive or therapeutic for infectious disease or cancer) within&#xD;
             2 weeks prior to initiation of study drug;&#xD;
&#xD;
          -  Infection with human immunodeficiency virus (HIV-1 or HIV-2), chronic infection with&#xD;
             hepatitis B or C, or acute infection with hepatitis A;&#xD;
&#xD;
          -  History of primary immunodeficiency;&#xD;
&#xD;
          -  History of serious, chronic autoimmune disease, eg, rheumatoid arthritis, systemic&#xD;
             lupus erythematosus, and multiple sclerosis;&#xD;
&#xD;
          -  Elective surgery planned during the study period through 30 days after discontinuation&#xD;
             of MEDI-538;&#xD;
&#xD;
          -  Autologous stem cell transplantation within 26 weeks prior to study entry;&#xD;
&#xD;
          -  Allogenic stem cell transplantation or any other solid organ transplant;&#xD;
&#xD;
          -  Cancer chemotherapy within 6 weeks prior to study entry;&#xD;
&#xD;
          -  Radiotherapy within 6 weeks prior to study entry;&#xD;
&#xD;
          -  Receipt of any investigational agent within 12 weeks prior to initiation of study&#xD;
             drug;&#xD;
&#xD;
          -  Treatment with rituximab within 12 weeks prior to study entry;&#xD;
&#xD;
          -  Prior treatment with alemtuzumab;&#xD;
&#xD;
          -  Regular dose of systemic corticosteroids during the 4 weeks prior to initiation of&#xD;
             study drug or anticipated need of corticosteroids exceeding prednisone 20 mg/day or&#xD;
             equivalent during the trial, or any other systemic immunosuppressive therapy within 4&#xD;
             weeks prior to study entry;&#xD;
&#xD;
          -  Any contraindication to chronic anticoagulation with low-molecular weight heparin&#xD;
             (LMWH);&#xD;
&#xD;
          -  Inability for safe placement and prolonged use (at least 8 weeks) of a central venous&#xD;
             catheter;&#xD;
&#xD;
          -  Contraindication to any of the protocol-specified concomitant medications&#xD;
             (methylprednisolone, antacids, or antihistamines) during this study;&#xD;
&#xD;
          -  Presence of human anti-murine antibodies or known hypersensitivity to immunoglobulins;&#xD;
&#xD;
          -  Pregnancy (sexually active females of childbearing potential must have a negative&#xD;
             urine pregnancy test on the day of the first dose of the study drug, prior to dosing)&#xD;
             or nursing;&#xD;
&#xD;
          -  Evidence of any uncontrolled systemic disease (other than B-cell NHL), any finding&#xD;
             upon physical examination or history of any disease that, in the opinion of the&#xD;
             investigator or medical monitor, may compromise the safety of the patient in the study&#xD;
             or confound the analysis of the study; or&#xD;
&#xD;
          -  Inability to meet social environment requirements for outpatient therapy (see Section&#xD;
             3.3.4.4).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen L. Kaucic, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>September 28, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <last_update_submitted>September 4, 2008</last_update_submitted>
  <last_update_submitted_qc>September 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Karen L. Kaucic, M.D.</name_title>
    <organization>MedImmune Inc.</organization>
  </responsible_party>
  <keyword>B-cell Non-Hodgkin's Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blinatumomab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

